Neurotrack's technology can diagnose Alzheimer's disease three to four years before symptoms appear, giving pharmaceutical companies and research organizations the tools to recruit truly qualified candidates for clinical trials and more effectively measure drug efficacy, speeding up drug discovery and development. Neurotrack is also on course to become the standard for early clinical screening of Alzheimer's and dementia related disorders.